Publicaciones en las que colabora con ANDREA MAYADO COLINO (25)

2024

  1. Engineered T cells secreting anti-BCMA T cell engagers control multiple myeloma and promote immune memory in vivo

    Science translational medicine, Vol. 16, Núm. 734, pp. eadg7962

  2. T-cell immune profile in blood of systemic mastocytosis: Association with disease features

    Allergy: European Journal of Allergy and Clinical Immunology

2023

  1. KITD816V mutation in blood for the diagnostic screening of systemic mastocytosis and mast cell activation syndromes

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 78, Núm. 5, pp. 1347-1359

2022

  1. Altered innate immune profile in blood of systemic mastocytosis patients

    Clinical and Translational Allergy, Vol. 12, Núm. 6

  2. Frequency and prognostic impact of blood-circulating tumor mast cells in mastocytosis

    Blood, Vol. 139, Núm. 4, pp. 572-583

2021

  1. Monocyte subsets and serum inflammatory and bone-associated markers in monoclonal gammopathy of undetermined significance and multiple myeloma

    Cancers, Vol. 13, Núm. 6, pp. 1-18

  2. Proposed global prognostic score for systemic mastocytosis: a retrospective prognostic modelling study

    The Lancet Haematology, Vol. 8, Núm. 3, pp. e194-e204

2020

  1. Detection of circulating tumor cells in blood of pancreatic ductal adenocarcinoma patients

    Cancer Drug Resistance, Vol. 3, Núm. 1, pp. 83-97

2019

  1. Bone marrow mast cell antibody-targetable cell surface protein expression profiles in systemic mastocytosis

    International Journal of Molecular Sciences, Vol. 20, Núm. 3

2018

  1. Characterization of CD34 + hematopoietic cells in systemic mastocytosis: Potential role in disease dissemination

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 73, Núm. 6, pp. 1294-1304

  2. Basophil-lineage commitment in acute promyelocytic leukemia predicts for severe bleeding after starting therapy

    Modern Pathology, Vol. 31, Núm. 8, pp. 1318-1331

  3. Impact of somatic and germline mutations on the outcome of systemic mastocytosis

    Blood Advances, Vol. 2, Núm. 21, pp. 2814-2828

2017

  1. Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature

    Oncotarget, Vol. 8, Núm. 40, pp. 68950-68963

2016

  1. Clinical, immunophenotypic, and molecular characteristics of well-differentiated systemic mastocytosis

    Journal of Allergy and Clinical Immunology, Vol. 137, Núm. 1, pp. 168-178.e1

  2. Diagnosis and classification of mastocytosis in non-specialized versus reference centres: A Spanish Network on Mastocytosis (REMA) study on 122 patients

    British Journal of Haematology, Vol. 172, Núm. 1, pp. 56-63

  3. Increased IL6 plasma levels in indolent systemic mastocytosis patients are associated with high risk of disease progression

    Leukemia, Vol. 30, Núm. 1, pp. 124-130

  4. KIT D816V-mutated bone marrow mesenchymal stem cells in indolent systemic mastocytosis are associated with disease progression

    Blood, Vol. 127, Núm. 6, pp. 761-768

2015

  1. Detection of the KIT D816V mutation in peripheral blood of systemic mastocytosis: Diagnostic implications

    Modern Pathology, Vol. 28, Núm. 8, pp. 1138-1149

  2. Ex vivo identification and characterization of a population of CD13high CD105+ CD45- mesenchymal stem cells in human bone marrow

    Stem Cell Research and Therapy, Vol. 6, Núm. 1

  3. The immunophenotype of mast cells and its utility in the diagnostic work-up of systemic mastocytosis

    Journal of Leukocyte Biology, Vol. 97, Núm. 1, pp. 49-59